Pfizer-BioNTech and Moderna Poised to Make Billions on COVID-19 Boosters

Share on facebook
Share
Share on twitter
Tweet
Share on whatsapp
WhatsApp
Moderna and the Pfizer-BioNTech alliance could reap billions from COVID-19 booster shots in the coming years, in what analysts and investors say could be a market comparable to the $6 billion in annual sales for flu vaccines. Pfizer, its German partner BioNTech, and Moderna have together locked in over $60 billion in sales of their respective COVID-19 vaccines through 2022, with the agreements covering initial doses and booster shots, according to Reuters.
Subscribe or log in to read the rest of this content.

Subscribe for Newsletter

Sign up to receive important news avoided by other media.

Scroll to Top